Inspire Medical Systems (NYSE:INSP) Announces FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.200-1.400 for the period, compared to the consensus estimate of 1.250. The company issued revenue guidance of $850.0 million-$860.0 million, compared to the consensus revenue estimate of $853.6 million.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $67.52 on Tuesday. The company has a market cap of $1.95 billion, a P/E ratio of 31.26, a PEG ratio of 5.37 and a beta of 0.73. The stock has a 50 day simple moving average of $68.69 and a two-hundred day simple moving average of $58.82. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $206.69 million for the quarter, compared to analyst estimates of $204.31 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The company’s revenue was down 7.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.38 earnings per share. On average, research analysts predict that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research note on Tuesday, August 4th. Zacks Research cut shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 22nd. Royal Bank Of Canada raised their price target on shares of Inspire Medical Systems from $60.00 to $75.00 and gave the stock a “sector perform” rating in a report on Thursday, October 1st. Finally, Weiss Ratings raised shares of Inspire Medical Systems from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $71.24.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter revenue of approximately $206.7 million, exceeding the $204.3 million consensus estimate. Adjusted earnings of $0.14 per share also topped published estimates of roughly $0.09–$0.10. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Management’s commentary pointed toward a potential recovery in the company’s reimbursement environment, which could support procedure volumes and growth if payer-related pressures ease. Inspire Medical Tops Consensus But Misses the Whisper
• Neutral Sentiment: The earnings call was closely watched by analysts for updates on reimbursement, demand and the company’s path back to sustained growth following recent operating challenges. Inspire Medical Systems Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined 7.9% from the year-ago quarter, while earnings fell to $0.14 per share from $0.38. The results indicate that reimbursement and utilization headwinds remain material despite the quarterly beat. Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Although INSP exceeded official consensus forecasts, reports indicate it missed higher “whisper” expectations, limiting the positive impact of the headline earnings beat and contributing to the weaker share-price reaction. Inspire Medical Tops Consensus But Misses the Whisper

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.